Author Question: A 78-year-old female receiving chemotherapy for breast cancer had a CBC performed after her last ... (Read 74 times)

newbem

  • Hero Member
  • *****
  • Posts: 579
A 78-year-old female receiving chemotherapy for breast cancer had a CBC performed after her last treatment. Her absolute neutrophil count was 1.0  109/L. What information can be concluded from this?
 
  a. The patient has a neutropenia in response to the chemotherapy.
  b. The patient has a neutropenia because of bone marrow failure.
  c. The patient has agranulocytosis.
  d. The patient has a neutrophilia in response to the breast cancer.

Question 2

The processing of a sample in a lavender top tube received in the lab at 10 a.m. is delayed because of a sudden fire drill. The sample is processed and analyzed at 2 p.m.
 
  Significant findings on this patient include an absolute neutrophil count of 1.5 x 109/L. What can be concluded from this?
 
  a. The patient is suffering from a neutropenia that needs to be investigated.
  b. The delay in testing resulted in a false neutropenia.
  c. The patient has pseudoneutropenia because of time of day the sample was drawn.
  d. There is not enough information to draw an accurate conclusion.



Benayers

  • Sr. Member
  • ****
  • Posts: 328
Answer to Question 1

Correct Answer: A

Answer to Question 2

Correct Answer: B



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

The heart is located in the center of the chest, with part of it tipped slightly so that it taps against the left side of the chest.

Did you know?

During the twentieth century, a variant of the metric system was used in Russia and France in which the base unit of mass was the tonne. Instead of kilograms, this system used millitonnes (mt).

Did you know?

Human kidneys will clean about 1 million gallons of blood in an average lifetime.

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library